Nociceptinergic System as Potential Target in Parkinson’s Disease

Author(s): Kornelia Tekes, Saeed Tariq, Ernest Adeghate, Rudolf Laufer, Farzad Hashemi, Afshan Siddiq, Huba Kalasz

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 13 , Issue 10 , 2013

Become EABM
Become Reviewer
Call for Editor


Nociceptinergic system has become an important target for drug development since the identification of the “orphan”, opioid-like-1 receptor and the isolation of its endogenous agonist nociceptin. Involvement of nociceptinergic system has been verified in a wide range of pathophysiological processes. A large number of nociceptinergic agonists and antagonists with peptide and non-peptide structures have been developed. Several non-peptide nociceptinergic antagonists have recently shown effective on different animal models of parkinsonism. Neuropharmacological background for antiparkinsonian effect of nociceptinergic antagonists, experimental models with high predictive value, nociceptinergic antagonists shown to have potential effect in Parkinson’s disease are summarized. Medicinal chemistry data (logP and TPSA) of the NOP receptor antagonists which are found to be effective in animal models of Parkinson’s disease are provided.

Keywords: Animal models of Parkinson’s disease, antiparkinsonian effect, medicinal chemistry data, NOP receptor antagonists, logP, TPSA.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 30 June, 2013
Page: [1389 - 1397]
Pages: 9
DOI: 10.2174/13895575113139990006
Price: $65

Article Metrics

PDF: 7